Table 1.

DawnRank analysis of entinostat-treated MMTV/Neu samples

Untreated (N = 6)			Entinostat-3wks (N = 4)			Entinostat-6wks (N = 4)			Entinostat-resistant (N = 8)
Gene	Percent rank	Chr	Gene	Percent rank	Chr	Gene	Percent rank	Chr	Gene	Percent rank	Chr
MAX	1	12	JUN	0.977	4	JUN	0.997	4	JUN	0.999	4
CALM1	0.995	12	CDC42	0.975	4	CDC42	0.994	4	JAK1	0.995	4
HIF1A	0.990	12	JAK1	0.969	4	JAK1	0.992	4	CDC42	0.990	4
ACTN1	0.986	12	LCK	0.969	4	LCK	0.989	4	CDKN2A	0.989	4
FOS	0.981	12	LYN	0.965	4	LYN	0.987	4	LCK	0.987	4
HSP90AA1	0.976	12	MAP3K7	0.960	4	MAP3K7	0.984	4	TGFBR1	0.984	4
FOXA1	0.972	12	ERBB2	0.959	11	CDKN2A	0.982	4	LRP8	0.983	4
ARF6	0.967	12	CDKN2A	0.952	4	ZBTB17	0.979	4	ZBTB17	0.981	4
FBLN5	0.963	12	TGFBR1	0.950	4	TGFBR1	0.977	4	TLE1	0.980	4
NCOA1	0.958	12	RBBP4	0.948	4	RBBP4	0.974	4	LYN	0.980	4
NFKBIA	0.953	12	ZBTB17	0.944	4	LRP8	0.972	4	RBBP4	0.979	4

Chr, mouse chromosome; Entinostat-3wks, Entinostat-6wks, Entinostat-resistant are samples treated with entinostat for 3 weeks, 6 weeks, and until progression, respectively